Selective CellCept therapy in high-risk renal transplant recipients.
Isenberg
A
A
Department of Surgery, Albany Medical College, New York 12208, USA.
Singh
T P
TP
Shen
G K
GK
Freed
B M
BM
Conti
D J
DJ
D000328:Adult; D001379:Azathioprine / Q000627:therapeutic use; D016572:Cyclosporine / Q000627:therapeutic use; D003922:Diabetes Mellitus, Type 1; D003928:Diabetic Nephropathies / Q000601:surgery; D004359:Drug Therapy, Combination; D006084:Graft Rejection / Q000517:prevention & control*; D006085:Graft Survival; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology* / Q000401:mortality; D009173:Mycophenolic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011183:Postoperative Complications / Q000453:epidemiology; D011241:Prednisone / Q000627:therapeutic use; D012086:Reoperation; D012189:Retrospective Studies; D015996:Survival Rate
D007166:Immunosuppressive Agents; D016572:Cyclosporine; D009173:Mycophenolic Acid; D001379:Azathioprine; D011241:Prednisone